Vertex Pharmaceuticals (VRTX) 10-K Summary — Year Ended Dec 31, 2025
Vertex Pharmaceuticals focuses on developing and commercializing therapies for serious diseases. The filing shows revenue growth and strong operating cash flow, but reports a prior-year operating cash outflow related to an acquisition.
Key takeaway
Year ended Dec 31, 2025 · FY2025 10-K
Vertex Pharmaceuticals focuses on developing and commercializing therapies for serious diseases. The filing shows revenue growth and strong operating cash flow, but reports a prior-year operating cash outflow related to an acquisition.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$12B
Revenue reported for the fiscal year.
Operating income
$4.2B
Income from operations reported for the year.
Net income
$4B
Net income reported for the year.
Operating cash flow
$3.6B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2022 | $8.9B | +17.9% |
| Dec 31, 2023 | $9.9B | +10.5% |
| Dec 31, 2024 | $11B | +11.7% |
| Dec 31, 2025 | $12B | +8.9% |
Business overview
The company is a biotechnology firm that discovers, develops, and markets medicines for serious conditions. Its business overview is outlined in Item 1 of the filing, with executive officers listed.
Financial performance
Annual revenue reached the reported figure, with operating income and net income also disclosed. Operating cash flow was positive for the latest period, compared to a negative figure in the prior year, which was attributed to an acquisition.
Material risks
Risk factors are detailed in Item 1A of the filing, covering typical industry risks such as regulatory challenges, competition, and dependence on key products. No specific new risks are highlighted beyond those standard to the sector.
Liquidity and capital
The company reported increased working capital driven by product revenue growth and higher inventory to support new product launches. Cash provided by operations was strong in the latest year.
What to watch
Monitor whether operating cash flow remains positive after the prior year’s acquisition-related outflow.